Research Areas

A Randomized Double Blind Placebo and Active Controlled Parallel Group Phase 2 Study to Evaluate An Investigational Medication as a Monotherapy and as an Add-On to Pregabalin for the Treatment of Painful Diabetic Peripheral Neuropathy

Multi-Center, Randomized, Home-Use Study of the Investigational Pen Needle and Currently Marketed Pen Needle To Compare Glycemic Control in Subjects with Diabetes Mellitus

Phase III, Active-Controlled, Safety and Efficacy Trial of An Investigational Oral Testosterone Undecanoate in Hypogonadal Men.

A Double-Blind, Multiple-Dose, 52-Week Study to Evaluate the Efficacy and Safety of An Investigational Testosterone Medication Administered Subcutaneously Once Each Week to Adult Males with Hypogonadism.

Clinical Evaluation of the Accuracy of An Investigational Continuous Glucose Monitoring System (CM)

Clinical Evaluation of the Accuracy of An Investigational Continuous Glucose Monitoring System (CM)

A Phase III, 52 Week, Randomized, Double-Blind, 3-Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination With the Fixed Dose Dual Combination, All Administered Once-Daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease.

A Phase II Dose-Range Finding Study of an investigational medication in patients with Type 2 Diabetes.

A Randomized, 24-Week, Open-Label, 2-Arm Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of A Combination of Two Marketed Drugs Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients.

The Impact of An Investigational Medication Versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Preprandial Insulin Lispro: a Double-Blind, Randomized, 26 Week Study

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition to Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin

A Phase 3, Multi-Center, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Efficacy and Safety of An Investigational Inhaled Prandial Insulin Versus Investigational Inhaled Insulin (Placebo) in Insulin Naïve Subjects with Type 2 Diabetes Mellitus Poorly Controlled with Oral Antidiabetic Agents Over a 24-week Treatment Period.

Six-Month, Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of A Marketed Basal Insulin and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Non-Insulin Anti-hyperglycemic Drugs with a 6-month Safety Extension Period

The Effect of a Marketed GLP-1 Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects with Type 2 Diabetes

Phase 2b Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group Study to Assess the Pharmacodynamics Response and Safety and Tolerability of Three Dose Levels of An Investigation Medication Injection Following 20 Weeks of Once-Weekly Subcutaneous Dosing in Adult Subjects With Inadequately Treated Type 2 Diabetes Mellitus

The Impact of An Investigational Insulin Versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study

A Phase 3, Multicenter, Open-Label, Randomized, Forced-Titration Clinical Trial Evaluating the Efficacy and Safety of An Investigational Insulin Inhalation Powder in Combination with a Basal Insulin Versus Insulin Aspart in Combination with a Basal Insulin in Subjects with Type 1 Diabetes Mellitus Over a 24-Week Treatment Period

A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of An Investigational Insulin Compared to Insulin Lispro (Humalog) in Subjects with Type 1 Diabetes Using Basal-Bolus Insulin Injection Therapy

Six-Month, Multicenter, Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of A Marketed Basal Insulin and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a Six-Month Safety Extension Period

Collection of normal blood samples for use in genetic studies for Breast Cancer